Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

BACKGROUND: Both the type I insulin-like growth factor receptor (IGF1R) and Src pathways are associated with the development and progression of numerous types of human cancer, and Src activation confers resistance to anti-IGF1R therapies. Hence, targeting both IGF1R and Src concurrently is one of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ho Jin, Pham, Phuong Chi, Hyun, Seung Yeob, Baek, Byungyeob, Kim, Byungjin, Kim, Yunha, Min, Hye-Young, Lee, Jeeyeon, Lee, Ho-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817804/
https://www.ncbi.nlm.nih.gov/pubmed/29455661
http://dx.doi.org/10.1186/s12943-018-0802-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817804/
https://www.ncbi.nlm.nih.gov/pubmed/29455661
http://dx.doi.org/10.1186/s12943-018-0802-4

Ejemplares similares